Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 55%
Buy 32%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is expected to continue leading the market with its strong management, innovative technology, and promising results in the use of CGM systems, especially in conjunction with other treatments for type 2 diabetes. Its commitment to addressing major health concerns and expanding into new markets while maintaining a positive financial outlook makes it a solid choice for investment. Despite potential competition and risks in the diabetes device sector, DexCom's track record and potential for growth make it an attractive investment opportunity.

Bears say

DexCom is facing potential risks in the T1 segment as well as potential challenges in expanding into the T2 market, with potential barriers including significant investments and competition from other non-insulin glucose lowering agents. Additionally, potential delays in market expansion and slower adoption of the 15-day sensors could hinder revenue growth and impact the company's margins. The current valuation multiple of 4.7x EV/Sales appears to be too low for a company with expected low-teens/20%+ revenue and EPS growth in 2026-2027, especially if one takes into account potential execution discounts. Management expects a 1H26 NIT RCT readout, but the current growth trend in the US has been decelerating, presenting further challenges to the company's growth prospects.

DexCom (DXCM) has been analyzed by 22 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 32% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 22 analysts, DexCom (DXCM) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.